The Osteocyte as a Director of Bone Metabolism

• Published in: Archives of rheumatology Vol. 36; no. 4; pp. 617 - 619
• Main Author: Benlidayi, Ilke Cockun
• Format: Journal Article
• Language: English
• Published: Istanbul Turkish League Against Rheumatism 01-12-2021; Prof Sebnem Ataman, President Turkish League Against Rheumatism
• Subjects: Authorship; Bone diseases; Denosumab; Fractures; Letter; Metabolism; Multiple sclerosis; Osteoporosis; Physiological aspects; Rheumatoid arthritis
• ISSN: 2148-5046; 1309-0291; 2618-6500; 1309-0283
• DOI: 10.46497/ArchRheumatol.2021.8632

Osteoporosis affects not only postmenopausal women and elderly individuals, but also patients with certain diseases such as neurological conditions (i.e., multiple sclerosis) and rheumatologic diseases (i.e., rheumatoid arthritis).5,6 Bone remodeling is a physiological process involving the regulated balance among bone cells (bone-lining cells, osteocytes, osteoclasts, and osteoblasts).7 Osteocytes are descended from mature osteoblasts. Distinct signaling molecules such as receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG), Dickkopf-1 (Dkk-1) and sclerostin provide osteocytes to communicate with osteoblasts and osteoclasts.1,8 They also secrete molecules such as parathyroid hormone related peptide (PTHrP), prostaglandin E2 (PGE2), and osteopontin (OPN).9 Osteocytes are mechanosensory cells responding to mechanical stimulation applied to the bone. Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases.